Skip to main content

Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood–Brain Barrier Proceedings of a Workshop (2018) / Chapter Skim
Currently Skimming:

Appendix B: Workshop Agenda
Pages 45-50

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 45...
... Few therapeutic agents readily traverse the BBB to reach the brain or spinal cord, including most small-molecule drugs and the vast majority of large molecules, such as proteins. Several research groups are exploiting intrinsic BBB transport mechanisms, such as molecular Trojan horses, and exploring technologies, such as chemical modifications and physical disruption, to test delivery of therapeutic agents to the CNS.
Read the entire page →
From page 46...
... • Discuss BBB passive and active mechanisms that challenge de velopment and delivery of effective therapeutic interventions to CNS targets. • Highlight current data and innovative approaches for delivery of therapeutics across the BBB harnessing methods, including chem ical modifications, Trojan horse approaches, physical targeting and disruption, nanoparticles, ultrasound, and other technologies.
Read the entire page →
From page 47...
... Break SESSION 1: TRAVERSING THE BBB: MODALITIES AND TECHNOLOGIES FOR BRAIN DELIVERY Session Objectives: • Describe current understanding of modalities for traversing the BBB. • Survey innovative technologies -- including Trojan horse approaches, physical targeting and disruption, nanoparticles, and ultrasound -- for delivery of therapeutics to the CNS.
Read the entire page →
From page 48...
... 11:25 a.m. Presentations BALU CHAKRAVARTHY, National Research Council of Canada ALEXANDRA GOLBY, Brigham and Women's Hospital RUBEN BOADO, ArmaGen DAHAVALKUMAR SHAH, State University of New York at Buffalo 12:25 p.m.
Read the entire page →
From page 49...
... • Explore issues related to critical attributes and potency assays; safety, including immunogenicity and CNS toxicity; and animal models, including appropriate species selection. • Explore best practices and strategies to facilitate regulatory consideration of novel technologies for traversing the BBB.
Read the entire page →
From page 50...
... ANTONIO CHIOCCA, Session 2 Co-Moderator FRANCESCA BOSETTI, Panel 1 Moderator 3:30 p.m. Panel Remarks BERND STOWASSER, Sanofi ANDREW WELCHMAN, Wellcome Trust EDMUND TALLEY, National Institute for Neurological Disorders and Stroke/BRAIN Initiative KATJA BROSE, Chan Zuckerberg Initiative GRANT CAMPANY, XPRIZE Foundation 5:00 p.m.
Read the entire page →

Key Terms

  • neurological disorders
  • transport mechanisms
  • eric schaeffer
  • therapeutic agents
  • trojan horse

  • janssen research
  • potential opportunities
  • spinal cord
  • key experts
  • physical disruption

  • chemical modifications
  • highlight gaps
  • danica stanimirovic
  • mechanisms challenging
  • bbb harnessing

  • appropriate species
  • physical barrier
  • explore novel
  • antonio chiocca
  • explore current

  • describe current
  • provide background
  • ily traverse
  • current understanding
  • francesca bosetti

  • edmund talley
  • active transport
  • innovative approaches
  • zuckerberg initiative
  • partnerships session


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.